retatrutide results is a triple hormone agonist used for significant weight reduction in individuals with overweight, obesity, and/or type 2 diabetes. It works by activating the GIP, GLP-1, and glucagon receptors, leading to Retatrutide Before and After: Doctor

Acetyl GLP-1+GIP supports fat loss and metabolic regulation by mimicking incretin hormones, enhancing insulin sensitivity, and reducing appetite

(25:03) Introducing MAPS

See what the science says before you buy.

These newer agents may further assist in the effective pharmacological management of T2D through the provision of patient-centered care that acknowledges multimorbidity and is respectful of and responsive to individual patient preferences and barriers

In February 2026, the FDA publicly announced its intent to take action targeting mass-marketed, non-FDA-approved compounded GLP1 products, emphasizing that promotional claims implying equivalence to FDAapproved drugs can trigger enforcement risk

GLP1 agonists may risk muscle loss